Australia Oncology Market Outlook to 2033 - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

1.1 List of Tables
1.2 List of Figures

2.1 What Is This Report About?
2.2 Oncology Market Segmentation
2.3 Definitions of Markets Covered in the Report

3.1 Oncology Market, Australia, Revenue ($m), 2018-2033
3.1.1 ALK Tests Market, Australia, Revenue ($m), by Segment, 2018-2033
3.1.2 BCR-ABL Tests Market, Australia, Revenue ($m), by Segment, 2018-2033
3.1.3 BRAF Tests Market, Australia, Revenue ($m), by Segment, 2018-2033
3.1.4 BRCA Tests Market, Australia, Revenue ($m), by Segment, 2018-2033
3.1.5 Colorectal Cancer Screening Tests Market, Australia, Revenue ($m), by Segment, 2018-2033
3.1.6 EGFR Tests Market, Australia, Revenue ($m), by Segment, 2018-2033
3.1.7 HER2 Tests Market, Australia, Revenue ($m), by Segment, 2018-2033
3.1.8 KRAS Tests Market, Australia, Revenue ($m), by Segment, 2018-2033
3.2 Oncology Market, Australia, Volume (Units), 2018-2033
3.2.1 ALK Tests Market, Australia, Volume (Units), by Segment, 2018-2033
3.2.2 BCR-ABL Tests Market, Australia, Volume (Units), by Segment, 2018-2033
3.2.3 BRAF Tests Market, Australia, Volume (Units), by Segment, 2018-2033
3.2.4 BRCA Tests Market, Australia, Volume (Units), by Segment, 2018-2033
3.2.5 Colorectal Cancer Screening Tests Market, Australia, Volume (Units), by Segment, 2018-2033
3.2.6 EGFR Tests Market, Australia, Volume (Units), by Segment, 2018-2033
3.2.7 HER2 Tests Market, Australia, Volume (Units), by Segment, 2018-2033
3.2.8 KRAS Tests Market, Australia, Volume (Units), by Segment, 2018-2033
3.3 Oncology Market, Australia, Average Price ($) , 2018-2033
3.4 Oncology Market, Australia, Company Share by Revenue ($m), 2024

4.1 F. Hoffmann-La Roche Ltd
4.1.1 Company Overview
4.2 Agilent Technologies Inc
4.2.1 Company Overview
4.3 Abbott Laboratories
4.3.1 Company Overview
4.4 Roche Diagnostics International Ltd
4.4.1 Company Overview
4.5 Qiagen NV
4.5.1 Company Overview
4.6 Eiken Chemical Co Ltd
4.6.1 Company Overview
4.7 Danaher Corp
4.7.1 Company Overview
4.8 bioMerieux SA
4.8.1 Company Overview
4.9 Thermo Fisher Scientific Inc
4.9.1 Company Overview
4.10 Resonac Corporation
4.10.1 Company Overview

6.1 Equity Offerings
6.1.1 Imagion Biosystems to Raise USD0.11 Million in Tranche 1 Private Placement of Shares
6.1.2 Imagion Biosystems to Raise USD2 Million in Private Placement of Shares
6.1.3 Genetic Technologies Raises USD0.21 Million in Entitlement Offering of Shares
6.1.4 OncoSil Medical to Raise USD1.78 Million in Private Placement of Shares
6.1.5 INOVIQ Raises USD4.62 Million in Private Placement of Shares
6.1.6 INOVIQ to Raise USD1.32 Million in SPP of Shares
6.1.7 Opthea Raises USD113.10 Million in Private Placement of Shares
6.1.8 BCAL Diagnostics to Raise USD4.12 Million in First Tranche Private Placement of Shares
6.1.9 BCAL Diagnostics to Raise USD2.86 Million in Second Tranche Private Placement of Shares

7.1 Corporate Communications
7.1.1 Oct 08, 2024: Opthea Announces New Senior Hires
7.1.2 Oct 08, 2024: National Accreditation Program for Breast Centers Optimal Resources for Breast Care Standards updated to recommend use of Lymphoedema Prevention Programs, including Bioimpedance Spectroscopy
7.1.3 Jun 24, 2024: Clarity Receives $10 million R&D Tax Incentive Refund
7.2 Other Significant Developments
7.2.1 Feb 11, 2025: Alcidion Receives Contract With Hywel Dda University Health Board in Wales
7.2.2 Nov 25, 2024: ACRF Awards $20 Million to Support Transformative Australian Cancer Research: World-First Total-Body PET/CT Scanning Tech; Reducing Childhood Cancer Deaths; And Revolutionising Immunotherapies
7.2.3 Nov 25, 2024: Australian Cancer Research Foundation Awards $5 Million Major Grant to Launch World-Leading Childhood Cancer Early Detection, Prevention and Treatment Program
7.2.4 Nov 25, 2024: ACRF Funding Enables Access to State-Of-The-Art Imaging Technology Set to Improve Immunotherapy Effectiveness and Reduce Toxicity Currently Experienced in up to 30% of Patients
7.2.5 Oct 22, 2024: Telix Spins off Rhine Pharma to Expand Global Access to Radiopharmaceuticals
7.2.6 Oct 08, 2024: National Accreditation Program for Breast Centers Optimal Resources for Breast Care Standards updated to recommend use of Lymphoedema Prevention Programs, including Bioimpedance Spectroscopy
7.2.7 Aug 05, 2024: 10x Genomics Technology Supports TenK10K Project Led by Garvan Institute of Medical Research to Help Transform the Treatment of Complex Diseases
7.3 Product News
7.3.1 May 29, 2025: Next-Gen Biobattery Shrinks Tumour, Paving Way for Drug-Free Cancer Treatments
7.3.2 Mar 24, 2025: Research Shows Importance of Genomic Testing and Targeted Therapies for Advanced Cancers
7.3.3 Mar 02, 2025: ONJCRI Researchers Pave the Way for Next-Generation Gene Editing in Cancer Research
7.3.4 Jan 16, 2025: Landmark Publication Highlights Diagnostic Potential of RoXsta
7.3.5 Dec 18, 2024: Clarity Announces Expansion of Pipeline With Novel Optimised FAP-Targeted Radiopharmaceutical
7.3.6 Oct 16, 2024: Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)
7.3.7 Aug 12, 2024: Promising New Target Discovered In Pancreatic Cancer Could Boost Chemotherapy And Reduce Spread
7.3.8 Jun 11, 2024: DEP presentation at SNMMI radiopharmaceuticals conference
7.4 Strategy And Business Planning
7.4.1 Jun 28, 2024: Sirtex Medical Partners with MediTrust Health to Explore Innovative Payment Models for Liver Tumor Patients in China

8.1 Research Methodology
8.1.1 Coverage
8.1.2 Secondary Research
8.1.3 Primary Research
8.1.4 Market Modeling and Forecasting
8.1.5 Company Share Analysis
8.1.6 Benchmarking
8.2 the analyst Consulting
8.3 Contact the Publisher
8.4 Disclaimer

Table 1: Oncology Market, Australia, Revenue ($m), USD Constant, 2018-2033
Table 2: ALK Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Table 3: BCR-ABL Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Table 4: BRAF Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Table 5: BRCA Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Table 6: Colorectal Cancer Screening Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Table 7: EGFR Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Table 8: HER2 Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Table 9: KRAS Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Table 10: Oncology Market, Australia, Volume (Units), 2018-2033
Table 11: ALK Tests Market, Australia, Volume (Units), 2018-2033
Table 12: BCR-ABL Tests Market, Australia, Volume (Units), 2018-2033
Table 13: BRAF Tests Market, Australia, Volume (Units), 2018-2033
Table 14: BRCA Tests Market, Australia, Volume (Units), 2018-2033
Table 15: Colorectal Cancer Screening Tests Market, Australia, Volume (Units), 2018-2033
Table 16: EGFR Tests Market, Australia, Volume (Units), 2018-2033
Table 17: HER2 Tests Market, Australia, Volume (Units), 2018-2033
Table 18: KRAS Tests Market, Australia, Volume (Units), 2018-2033
Table 19: Oncology Market, Australia, Average Price ($), 2018-2033
Table 20: Oncology Market, Australia, Company Share by Revenue ($m), 2024
Table 21: Oncology Market Pipeline Products
Table 22: Imagion Biosystems to Raise USD0.11 Million in Tranche 1 Private Placement of Shares
Table 23: Imagion Biosystems to Raise USD2 Million in Private Placement of Shares
Table 24: Genetic Technologies Raises USD0.21 Million in Entitlement Offering of Shares
Table 25: OncoSil Medical to Raise USD1.78 Million in Private Placement of Shares
Table 26: INOVIQ Raises USD4.62 Million in Private Placement of Shares
Table 27: INOVIQ to Raise USD1.32 Million in SPP of Shares
Table 28: Opthea Raises USD113.10 Million in Private Placement of Shares
Table 29: BCAL Diagnostics to Raise USD4.12 Million in First Tranche Private Placement of Shares
Table 30: BCAL Diagnostics to Raise USD2.86 Million in Second Tranche Private Placement of Shares
Table 31: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country

Figure 1: Oncology Market, Australia, Revenue ($m), USD Constant, 2018-2033
Figure 2: ALK Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Figure 3: BCR-ABL Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Figure 4: BRAF Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Figure 5: BRCA Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Figure 6: Colorectal Cancer Screening Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Figure 7: EGFR Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Figure 8: HER2 Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Figure 9: KRAS Tests Market, Australia, Revenue ($m), USD Constant, 2018-2033
Figure 10: Oncology Market, Australia, Volume (Units), 2018-2033
Figure 11: ALK Tests Market, Australia, Volume (Units), 2018-2033
Figure 12: BCR-ABL Tests Market, Australia, Volume (Units), 2018-2033
Figure 13: BRAF Tests Market, Australia, Volume (Units), 2018-2033
Figure 14: BRCA Tests Market, Australia, Volume (Units), 2018-2033
Figure 15: Colorectal Cancer Screening Tests Market, Australia, Volume (Units), 2018-2033
Figure 16: EGFR Tests Market, Australia, Volume (Units), 2018-2033
Figure 17: HER2 Tests Market, Australia, Volume (Units), 2018-2033
Figure 18: KRAS Tests Market, Australia, Volume (Units), 2018-2033
Figure 19: Oncology Market, Australia, Company Share (%), 2024